These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27398859)

  • 1. CROI 2016: Hot Spots in HIV Infection and Advances in HIV Prevention.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2016; 24(1):10-28. PubMed ID: 27398859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CROI 2015: Advances in HIV Testing and Prevention Strategies.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2015; 23(1):8-27. PubMed ID: 25965309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CROI 2018: Epidemic Trends and Advances in HIV Prevention.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2018 May; 26(1):1-16. PubMed ID: 29727292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CROI 2017: HIV Epidemic Trends and Advances in Prevention.
    Liu AY; Buchbinder SP
    Top Antivir Med; 2017; 25(2):35-50. PubMed ID: 28598789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual CROI 2020: Highlights of Epidemiology, Public Health, and Prevention Research.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2020 Jun; 28(2):439-454. PubMed ID: 32886464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CROI 2021: Epidemiologic Trends in the HIV and SARS-CoV-2 Pandemics and HIV Prevention Research.
    Buchbinder S; Liu A
    Top Antivir Med; 2021; 29(2):309-327. PubMed ID: 34107201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CROI 2014: New tools to track the epidemic and prevent HIV infections.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2014 May; 22(2):579-93. PubMed ID: 24901884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CROI 2023: Epidemiologic Trends and Prevention for HIV and Other Sexually Transmitted Infections.
    Liu AY; Buchbinder SP
    Top Antivir Med; 2023 May; 31(3):468-492. PubMed ID: 37315512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia.
    Kelley CF; Kahle E; Siegler A; Sanchez T; Del Rio C; Sullivan PS; Rosenberg ES
    Clin Infect Dis; 2015 Nov; 61(10):1590-7. PubMed ID: 26270691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CROI 2019: advances in HIV prevention and plans to end the epidemic.
    Buchbinder SP; Liu AY
    Top Antivir Med; 2019 Apr; 27(1):8-25. PubMed ID: 31136999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.
    Smith DK; Van Handel M; Wolitski RJ; Stryker JE; Hall HI; Prejean J; Koenig LJ; Valleroy LA
    MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1291-5. PubMed ID: 26606148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Prevention: Opportunities and Challenges.
    Marrazzo JM
    Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CROI 2022: epidemiologic trends and prevention for HIV and SARS-CoV-2.
    Buchbinder S; Liu A
    Top Antivir Med; 2022; 30(2):426-453. PubMed ID: 36346701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Willingness to Take, Use of, and Indications for Pre-exposure Prophylaxis Among Men Who Have Sex With Men-20 US Cities, 2014.
    Hoots BE; Finlayson T; Nerlander L; Paz-Bailey G;
    Clin Infect Dis; 2016 Sep; 63(5):672-7. PubMed ID: 27282710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical Implications of Social Stigma Associated with the Promotion and Use of Pre-Exposure Prophylaxis for HIV Prevention.
    Herron PD
    LGBT Health; 2016 Apr; 3(2):103-8. PubMed ID: 26859191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Care continuum entry interventions: seek and test strategies to engage persons most impacted by HIV within the United States.
    McNulty MC; Schneider JA
    AIDS; 2018 Feb; 32(4):407-417. PubMed ID: 29381558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea.
    Chang HH; Kim SW; Jung H; Lee SA; Park HK; Kim S; Lee JM; Choi JY
    J Korean Med Sci; 2018 Mar; 33(12):e91. PubMed ID: 29542300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.